Shanton Reveals Topline Data from Phase 2b Study in Refractory Gout Patients
SAP-001 is Shanton's lead investigational compound with First- and Best-in-Class potential in uncontrolled gout SINGAPORE and PRINCETON, N.J., March 28, 2025 /PRNewswire/ -- Shanton Pharma, a clinical-stage biotech company developing a novel...
Caliway Announces CBL-514 Second Phase 2b Study Results (CBL-0205) Met Endpoints
CBL-514, the world's first investigational drug for large-area localized fat reduction, has demonstrated significant efficacy in its second and the last Phase 2b study (CBL-0205) before Phase 3. 54.2% of participants in the CBL-514 group achieved at...